profit from every $100 of sales.
$0$100
Doximity
$33.20-0.06% today
-34.2% in 1 year
1-year low $18.011-year high $51.53
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2021 to 2026.
0%20% a year
You pay $30.21 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Doximity sold, what it kept, and what it did with the cash.
Sales went from $419 million in 2023 to $645 million in 2026, with $196 million of profit last year.
SalesProfit
Doximity handed back more cash to shareholders than it generated last year.
Buybacks $432M
Free cash flow 2026$317M
Bought back its own shares$432M
Paid as dividends–
Cash vs. debt$219M vs. $10M
Doximity vs. similar companies
Doximity grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Doximity | 30.2× · Expensive | ||
 Veeva Systems | 53.9× · Expensive | ||
 Pro Medicus | 183.9× · Very expensive | ||
 Hinge Health | No profit yet | ||
 M3 | 30.3× · Expensive |
AI analysis
Doximity sells a sticky doctor network and trades on growth slowing
Read the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| 207 | 344 | 419 | 475 | 570 | 645 | |
| 176 | 304 | 366 | 425 | 515 | 575 | |
| 53 | 114 | 125 | 172 | 230 | 215 | |
| 57 | 119 | 135 | 182 | 241 | 229 | |
| 50 | 155 | 113 | 148 | 223 | 196 | |
| 0.23 | 0.70 | 0.53 | 0.72 | 1.11 | 0.98 | |
| 84.9% | 88.4% | 87.2% | 89.3% | 90.2% | 89.1% | |
| 25.8% | 33.0% | 29.9% | 36.1% | 40.3% | 33.3% | |
| 24.3% | 45.1% | 26.9% | 31.0% | 39.1% | 30.4% |
Balance sheet
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Total assets | 252 | 991 | 1,137 | 1,079 | 1,264 | 1,124 |
| Cash | 66 | 113 | 158 | 97 | 210 | 219 |
| Total debt | – | – | 16 | 15 | 12 | 10 |
| Total liabilities | 104 | 113 | 171 | 178 | 182 | 173 |
| 67 | 879 | 966 | 901 | 1,083 | 951 | |
| 95 | 191 | 213 | 206 | 201 | 199 | |
| 63.1% | 10.2% | 10.1% | 14.8% | 16.6% | 17.7% | |
| 75.2% | 17.6% | 11.7% | 16.4% | 20.6% | 20.6% |
Cash flow
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| 83 | 127 | 180 | 184 | 273 | 326 | |
| – | – | 6 | 6 | 7 | 9 | |
| – | – | 173 | 178 | 267 | 317 | |
| Dividends paid | – | – | – | – | – | – |
| 2 | 3 | 85 | 281 | 120 | 432 | |
| 7 | 31 | 48 | 51 | 72 | 122 |
Valuation
- 30.2×
- 20.5×
- 0.90
- 6.2×
- 9.2×
- 18.7×
- 24.9×
- 5.4%
- 3.3%
- 0.0%
Profitability
- 89.1%
- 33.3%
- 30.4%
- 38.1%
- 18.1%
- 15.2%
- 19.4%
- 17.4%
- 22.2%
- 20.3%
Growth
- +25.5%
- +33.6%
- −100.0%
- –
- −2.3%
Financial health
- -0.9×
- 0.01
- 0.9%
- –
- 6.09
- 6.09
- 0.57
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 11%of 952
Top 7%of 883
Bottom 45%of 576
Top 22%of 870
Top 20%of 985
What analysts expect
- Average price target
- $42.79
- Range
- $25.00 – $63.00
- 13 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | 0.26 | 0.28 | −7.1% |
| Feb 5, 2026 | 0.46 | 0.44 | +4.5% |
| Nov 6, 2025 | 0.45 | 0.38 | +18.8% |
| Aug 7, 2025 | 0.36 | 0.30 | +19.4% |
| May 15, 2025 | 0.38 | 0.27 | +39.9% |
| Feb 6, 2025 | 0.45 | 0.31 | +45.2% |
| Nov 7, 2024 | 0.30 | 0.25 | +20.0% |
| Aug 8, 2024 | 0.28 | 0.22 | +27.3% |
News
Doximity (DOCS) Registers a Bigger Fall Than the Market: Important Facts to NoteYahoo Finance · Sep 15, 2026The newest story we have is from Sep 15, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
6/7Passes 6 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
76Pass
Benjamin Graham
62Pass
Philip Fisher
98Pass
Peter Lynch
100Pass
Joel Greenblatt
30No pass
Charlie Munger
86Pass
Terry Smith
84Pass
Questions about Doximity
Is Doximity a good stock to buy?
A strong, very profitable business, but the price is high. 6 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Doximity AI analysis
What does Doximity do?
Doximity, Inc. operates a digital platform for medical professionals in the United States. It is in Health Information Services, based in San Francisco, CA, United States, with 880 employees.
Does Doximity pay a dividend?
No. Doximity does not pay a dividend at the moment; in 2026 it returned $432 million to shareholders by buying back its own shares.
Is Doximity stock halal?
Yes. Doximity passes our halal screen: its business is permitted and its debt is 0.2% of its market value, under the 30% limit. How we check
How has Doximity stock done over the past year?
Down 34.2% over the past twelve months, to $33.20. It traded between $18.01 and $51.53 and is 35.6% below its high.
Who are Doximity's competitors?
The largest listed companies in the same industry are Veeva Systems, Pro Medicus, Hinge Health and M3. The peers table on this page compares their profit, growth and price with Doximity's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.